Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)

D Sun, M Novotny, K Bulek, C Liu, X Li… - Nature immunology, 2011 - nature.com
D Sun, M Novotny, K Bulek, C Liu, X Li, T Hamilton
Nature immunology, 2011nature.com
Abstract Interleukin 17 (IL-17) promotes the expression of chemokines and cytokines via the
induction of gene transcription and post-transcriptional stabilization of mRNA. We show here
that IL-17 enhanced the stability of chemokine CXCL1 mRNA and other mRNAs through a
pathway that involved the adaptor Act1, the adaptors TRAF2 or TRAF5 and the splicing
factor SF2 (also known as alternative splicing factor (ASF)). TRAF2 and TRAF5 were
necessary for IL-17 to signal the stabilization of CXCL1 mRNA. Furthermore, IL-17 promoted …
Abstract
Interleukin 17 (IL-17) promotes the expression of chemokines and cytokines via the induction of gene transcription and post-transcriptional stabilization of mRNA. We show here that IL-17 enhanced the stability of chemokine CXCL1 mRNA and other mRNAs through a pathway that involved the adaptor Act1, the adaptors TRAF2 or TRAF5 and the splicing factor SF2 (also known as alternative splicing factor (ASF)). TRAF2 and TRAF5 were necessary for IL-17 to signal the stabilization of CXCL1 mRNA. Furthermore, IL-17 promoted the formation of complexes of TRAF5-TRAF2, Act1 and SF2 (ASF). Overexpression of SF2 (ASF) shortened the half-life of CXCL1 mRNA, whereas depletion of SF2 (ASF) prolonged it. SF2 (ASF) bound chemokine mRNA in unstimulated cells, whereas the SF2 (ASF)-mRNA interaction was much lower after stimulation with IL-17. Our findings define an IL-17-induced signaling pathway that links to the stabilization of selected mRNA species through Act1, TRAF2-TRAF5 and the RNA-binding protein SF2 (ASF).
nature.com